The increasing use of NGS-based gene panels in the evaluation of thrombocytopenia will likely result in a growing number of RUNX1-FPDMM diagnoses and may, over time, improve estimates of lifetime malignancy risk—provided that unified surveillance protocols and consistent database documentation continue to be implemented. The gene discussed is RUNX1; the disease is Thrombocytopenia.